Flagship launches first UK-based startup to uncover genes that make cells vulnerable or resistant to disease
A new biotech startup believes that genetic diversity found among the trillions of cells that comprise an individual person could hold the keys to new clues for treating or preventing disease.
Flagship Pioneering, a life sciences investment firm that builds its own biotech startups, announced an initial $50 million commitment to Quotient Therapeutics at its launch from stealth on Tuesday morning.
In a first for Flagship, which usually keeps its companies close to its home base around Boston, Quotient launched with the majority of its employees in Cambridge, UK. A spokesperson for Flagship said the life sciences firm’s UK offices will officially open next week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.